Remdesivir for COVID-19: The NIAID Study Behind its Approval | GameChangers

from CEimpact Podcast · host Pharmacy Podcast Network

Recently, Remdesivir was given Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) for use in COVID based on a heretofore unpublished study. The study, conducted by NIAID, is the subject of this episode.This episode is accredited for CPE. For CE details and to claim credit click here: https://bit.ly/3hn191p See omnystudio.com/listener for privacy information.Follow CEimpact on Social Media:LinkedInInstagram

Episode metadata supplied by the publisher feed · Published Jun 12, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Remdesivir for COVID-19: The NIAID Study Behind its Approval | GameChangers

0:00 23:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of CEimpact Podcast?

This episode is 23 minutes long.

When was this CEimpact Podcast episode published?

This episode was published on June 12, 2020.

Can I download this CEimpact Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!